Royalty Pharma plc 8-K

What Happened

• Royalty Pharma plc held its 2026 Annual General Meeting on June 4, 2026 and filed the vote results on Form 8-K. A total of 508,180,103 Class A and Class B shares were present or represented by proxy, representing 88.08% of combined voting power and constituting a quorum.
• Shareholders voted on 10 proposals. All nine director nominees were elected (each by separate vote). Notable vote totals included Vlad Coric — 433,218,530 For / 54,472,087 Against, Pablo Legorreta — 458,242,360 For / 29,448,236 Against, and Elizabeth Weatherman — 487,564,658 For / 128,998 Against.
• Other key approvals: non-binding advisory vote on executive compensation passed (476,044,602 For, 11,067,486 Against); Ernst & Young LLP was ratified as the Company’s independent registered public accounting firm (506,307,829 For, 832,217 Against); and Ernst & Young was re‑appointed as the Company’s U.K. statutory auditor (506,752,136 For, 384,952 Against).

Key Details

• Shares present/represented: 508,180,103 (88.08% of voting power).
• Director elections: nine directors elected; notable opposition amounts — Vlad Coric 54,472,087 Against; Pablo Legorreta 29,448,236 Against.
• Say-on-pay (non-binding): 476,044,602 For; 11,067,486 Against; 747,086 Abstain; 20,320,929 broker non-votes.
• Share-authority and buyback-related votes: approval to permit share purchases (Proposal 8) — 474,475,427 For / 12,499,628 Against; authorizations to allot shares (Proposals 9 & 10) passed, with Proposal 10 (allot without pre-emption) receiving higher opposition (445,653,078 For / 42,016,406 Against).

Why It Matters

• Board continuity and governance: Election of all nine nominees keeps the board intact and confirms management’s slate; vote totals show varying levels of shareholder opposition on certain directors, which investors may watch as a governance signal.
• Corporate actions and capital flexibility: Approval of share purchase terms and authorizations to allot shares give the board flexibility for buybacks, equity issuance or other capital actions that can affect share count and shareholder value.
• Audit and oversight: Ratification and re-appointment of Ernst & Young for both U.S. and U.K. audits preserves audit continuity.
• Advisory votes (like say-on-pay) are non‑binding but indicate shareholder sentiment on executive compensation and can influence future compensation and governance decisions.